NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Thursday that its second quarter 2017 revenues climbed to $1.3 million, up 93 percent from $663,000 in Q2 2016 when including the conversion of accrual-based revenue recognition, and up 64 percent excluding the impact of the conversion.